Navigation Links
Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047
Date:5/14/2008

BRISBANE, Australia, May 14 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX:PGL; Nasdaq: PGLA) today announced that the Company has resumed patient enrolment in the phase 1 dose-escalation study of its recently acquired polyamine analogue, PG-11047 (formerly CGC-11047) for patients with advanced cancer.

Progen has commenced development of PG-11047 - the lead clinical compound in the Company's polyamine program - following its acquisition of Cellgate, Inc earlier this year. The first patient to be recruited into the trial re-initiation has been enrolled at the University of Chicago.

The trial is exploring the potential of PG-11047 as a single anti-cancer agent and is designed to assess the agent's maximum tolerated dose. Under CellGate, the trial had recruited 31 patients and had shown little evidence of toxicity, while using significantly higher doses than most previous studies of polyamine compounds.

Justus Homburg, Progen's CEO, said, "Since the acquisition of CellGate, we have been assessing our portfolio of clinical and pre-clinical compounds in order to determine which to drive forward. Our re-initiation of PG-11047 in phase 1 clinical development is the first step in driving potential value from our expanded portfolio of first-in-class oncology therapies."

Data from the trial will be used in parallel with a separate PG-11047 study assessing the agent in combination with other marketed anti-cancer drugs as the basis for determining potential phase 2 development. Progen expects the study to produce data within the next 12 months.

About Progen: Progen Pharmaceuticals is a globally focused biotechnology company committed to the discovery, development and commercialization of small molecule pharmaceuticals primarily for the treatment of cancer. Progen has operations in Australia and the US.

About PG-11047: PG-11047 is a polyamine analogue which modifies the production of natural polyamines. Polyamines are a class of chemical which are involved in regulation of cell growth. They are overproduced in many cancers, and PG-11047 is believed to restore polyamine reduction to natural levels. Despite being the focus of scientific interest for many years, this mechanism is unique, and if successful, PG-11047 could become a first-in-class oncology product. To date, PG-11047 has been shown to have anti-tumor activity in animal models, combined with a good safety profile.

Progen Information:

Justus Homburg, CEO

Progen Pharmaceuticals Limited

T: +61 7 3842 3333

E: justush@progen-pharma.com

Media and Investor Relations:

Cindy Ingram, Investor Relations Manager

Progen Pharmaceuticals Limited

T: +61 7 3842 3333

E: cindyi@progen-pharma.com

This press release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties, including without limitation, risks associated with drug development and manufacture, risks inherent in the extensive regulatory approval process mandated by the United States Food and Drug Administration and the Australian Therapeutic Goods Administration, delays in obtaining the necessary approvals for clinical testing, patient recruitment, delays in the conduct of clinical trials, market acceptance of PI-88, PI-166 and other drugs, future capital needs, general economic conditions, and other risks and uncertainties detailed from time to time in the Company's filings with the Australian Securities Exchange and the United States Securities and Exchange Commission. Moreover, there can be no assurance that others will not independently develop similar products or processes or design around patents owned or licensed by the Company, or that patents owned or licensed by the Company will provide meaningful protection or competitive advantages.


'/>"/>
SOURCE Progen Pharmaceuticals Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
2. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
3. Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
4. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
5. Progen Announces PI-88 Phase 2 Lung Cancer Results
6. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
7. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
8. Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
9. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
10. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
11. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... December 2, 2016 On Thursday, ... honored excellence in research, development and innovation in the ... dinner was held in the presence of Sergey Tsyb, ... Russian Federation , Natalia Sanina, First Vice ... Murashko , Head of Roszdravnadzor, National Service of Control ...
(Date:12/2/2016)... Columbia , December 2, 2016 bioLytical Laboratories, ... INSTI HIV-Selbsttest, bei den Mitgliedern des Apothekenbundes von Kenia eingeführt. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ...
(Date:12/2/2016)... 2, 2016 Lianluo Smart Limited (Nasdaq: ... Company") which develops, markets and sells medical devices ... China and international markets, recently attended ... Treatment New Progress Forum, co-hosted by the Institute ... , Guangdong Provincial People,s Hospital and Cardiology ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 03, 2016 , ... "Perfect Harmony comes with ... allowing FCPX editors to create professional looking video in a matter of minutes," ... contains a beautifully designed 3D environment for placing in personal media. Twenty pre-made ...
(Date:12/4/2016)... Aliso Viejo, California (PRWEB) , ... December 04, ... ... self-animating lower third presets that have new attractive animation styles with unique displacement ... Pro3rd Displace features 30 pre-animated lower third designs. Choose from a variety of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Halfway through its partnership with First 5 ... services to more than 15,900 children 5 years old and younger and treatment services ... over a span of five years to Western University of Health Sciences, UCLA and ...
(Date:12/2/2016)... ... 02, 2016 , ... For over twenty-four years, Doctors on Liens has published a ... find high quality medical care. When the company started in 1997, the directory was ... present day and the now ten-page directory features a vast array of medical specialists ...
(Date:12/2/2016)... ... ... Center for Autism and Related Disorders (CARD) Portland today announced plans to ... and other developmental disabilities. The group, which is being launched with the help of ... to share stories and advice, seek help, and continue their education on how to ...
Breaking Medicine News(10 mins):